Elimination of Cancer Stem–Like Side Population in Human Glioblastoma Cells Accompanied With Stemness Gene Suppression by Korean Herbal Recipe MSC500. (November 2014)

• Record Type: Journal Article
• Authors: Yao, Chih-Jung; Han, Tae-Young; Shih, Ping-Hsiao; Yi, Tsu-Yi; Lai, I-Chun; Chang, Ken-Hu; Lai, Tung-Yuan; Chang, Chia-Lun; Lai, Gi-Ming
• Is Part Of: Integrative cancer therapies. Volume 13:Number 6(2014:Nov.)
• Page Start: 541
• Page End: 554
• Publication Date: 2014-11
• Subjects: glioma -- cancer stem cell -- MSC500 -- ALDH -- E-cadherin; Cancer -- Alternative treatment -- Periodicals; 616.99406
• DOI: 10.1177/1534735414549623
• Languages: English
• ISSNs: 1534-7354

Abstract

Background: High-grade gliomas are the most common and invasive malignant brain tumors in adults, and they are almost universally fatal because of drug resistance and recurrence. In spite of the progress in adjuvant therapy (like temozolomide) and irradiation after surgery, no effective salvage therapy is currently available for relapsed patients. A Korean herbal recipe MSC500 has been reported to have beneficial therapeutic effects in patients with high-grade gliomas who are relapsed or refractory to conventional treatments. But the underlying molecular mechanisms remain unclear.Methods: As Cancer stem cell (CSC) plays a pivotal role in the resistance to conventional cancer therapy, we explored the effects of MSC500 on the CSC-like side population (SP) in GBM8401 human glioblastoma multiforme cells. Results : Compared with the parental cells, the SP cells were more resistant to temozolomide but sensitive to MSC500. The mRNA levels of stemness genes such as Nanog, CD133, and ABCG2 were much higher in the SP cells, and so was E-cadherin, which was reported to correlate with the aggressiveness of glioblastoma multiforme. Treatment with MSC500 decreased the proportion of SP cells and high ALDH activity cells from 1.6% to 0.3% and from 0.9% to 0.1%, respectively, accompanied with suppression of the aforementioned stemness genes and E-cadherin, as well as other CSC markers such as ABCB5, Oct-4, Sox-2, β-catenin, Gli-1, and Notch-1. Conclusion : Our results suggest the potential role of MSC500 as an integrative and complementary therapeutic for advanced or refractory high-grade glioma patients.